Quick Takeaways
- SILO - Silo Pharma, Inc. has 5 insiders with reported activity on this page.
- Net insider value flow over the last year: +$11,986.
- Recent transaction rows are available for direct filing-level review.
- Info
- Insider Trading
- Financials
Insider Transactions Reported by 5 Insiders of Silo Pharma, Inc.
- Symbol
- SILO on Nasdaq
- Location
- Sarasota, FL
What Changed
- Buy value: $11,986; sell value: $0.
- Net share flow: +29,000.
Why This Matters
- This page gives a plain-language issuer insider context before you inspect transaction-level evidence.
- Use the filing links below to verify timestamps, codes, and ownership impacts directly from SEC forms.
Source Evidence
Filed on Form 4
See Original Filing
Issuer insider activity is sourced from SEC Forms 3, 4, and 5.
Insider trading overview
Last 12 monthsNet insider flow leans to buying over the last 12 months. Net value: +$11,986.
Buys
$11,986
Shares: 29,000
Insiders: 1
Sells
$0
Shares: 0
Insiders: 0
Net
+$11,986
Shares: +29,000
Insiders: 1
| Window (months) | Buy shares | Sell shares | Buy $ | Sell $ | Net $ |
|---|---|---|---|---|---|
| 0-3 | 0 | 0 | $0 | $0 | $0 |
| 3-6 | 19,000 | 0 | $7,657 | $0 | +$7,657 |
| 6-9 | 0 | 0 | $0 | $0 | $0 |
| 9-12 | 10,000 | 0 | $4,329 | $0 | +$4,329 |
Silo Pharma, Inc. executives and other stock owners filed with the SEC include:
| Name | Relationship | Holdings Value | Past Year Net Change | Change % | Valuation | Report Date |
|---|---|---|---|---|---|---|
| Eric Weisblum | Chief Executive Officer, Director | $91,111 | +$11,986 | +15% | Filing P/S | 15 Dec 2025 |
| Jeff Pavell | Director | Mixed | 23 May 2025 | |||
| Kevin Munoz | Director | Mixed | 23 May 2025 | |||
| Wayne Linsley | Director | Mixed | 23 May 2025 | |||
| Daniel E. Ryweck | Chief Financial Officer | Mixed | 23 May 2025 |
Top shareholders of Silo Pharma, Inc. (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.
Methodology: rows are grouped by holder and ranked by the holder's primary source value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
| Holder | Source | Role / Reporting | Ownership % | Shares | Holdings Value | 12M Net Δ | As of | Details |
|---|---|---|---|---|---|---|---|---|
| INTRACOASTAL CAPITAL, LLC |
13D/G
|
Mitchell P. Kopin |
10%
|
1,478,164
|
$561,702 | +$35,627 | 31 Dec 2025 | |
| Anson Funds Management LP |
13D/G
|
— |
4.9%
|
699,486
|
$265,805 | -$96,100 | 31 Dec 2025 | |
| AdvisorShares Investments LLC |
13F
|
Company |
4.2%
|
599,507
|
$203,832 | — | 31 Dec 2025 | |
| DRW Securities, LLC |
13F
|
Company |
2.3%
|
333,733
|
$113,469 | — | 31 Dec 2025 | |
| Eric Weisblum |
3/4/5
|
Chief Executive Officer, Director |
—
mixed-class rows
|
604,864
mixed-class rows
|
$91,111 | +$11,986 | 15 Dec 2025 | |
| GEODE CAPITAL MANAGEMENT, LLC |
13F
|
Company |
0.65%
|
92,905
|
$31,587 | — | 31 Dec 2025 | |
| RENAISSANCE TECHNOLOGIES LLC |
13D/G
|
— |
0.84%
|
37,500
|
$30,375 | -$153,500 | 31 Dec 2024 | |
| XTX Topco Ltd |
13F
|
Company |
0.4%
|
56,899
|
$19,346 | — | 31 Dec 2025 | |
| JANE STREET GROUP, LLC |
13F
|
Company |
0.24%
|
34,373
|
$11,687 | — | 31 Dec 2025 | |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP |
13F
|
Company |
0.21%
|
29,577
|
$10,056 | — | 31 Dec 2025 | |
| VANGUARD GROUP INC |
13F
|
Company |
0.17%
|
24,321
|
$8,269 | — | 31 Dec 2025 | |
| Virtu Financial LLC |
13F
|
Company |
0.13%
|
18,418
|
$6,000 | — | 31 Dec 2025 | |
| STATE STREET CORP |
13F
|
Company |
0.09%
|
12,500
|
$4,250 | — | 31 Dec 2025 | |
| UBS Group AG |
13F
|
Company |
0.04%
|
6,043
|
$2,054 | — | 31 Dec 2025 | |
| CITIGROUP INC |
13F
|
Company |
0.02%
|
3,451
|
$1,173 | — | 31 Dec 2025 | |
| Tower Research Capital LLC (TRC) |
13F
|
Company |
0.01%
|
1,695
|
$576 | — | 31 Dec 2025 | |
| BANK OF AMERICA CORP /DE/ |
13F
|
Company |
0%
|
113
|
$38 | — | 31 Dec 2025 | |
| Westside Investment Management, Inc. |
13F
|
Company |
0%
|
94
|
$32 | — | 31 Dec 2025 | |
| WELLS FARGO & COMPANY/MN |
13F
|
Company |
0%
|
10
|
$3 | — | 31 Dec 2025 | |
| Daniel E. Ryweck |
3/4/5
|
Chief Financial Officer |
—
class O/S missing
|
55,000
|
— | — | 23 May 2025 | |
| Kevin Munoz |
3/4/5
|
Director |
—
class O/S missing
|
53,425
|
— | — | 23 May 2025 | |
| Wayne Linsley |
3/4/5
|
Director |
—
class O/S missing
|
53,425
|
— | — | 23 May 2025 | |
| Jeff Pavell |
3/4/5
|
Director |
—
class O/S missing
|
50,000
|
— | — | 23 May 2025 |
Recent Insider Transactions by Companies or Individuals for Silo Pharma, Inc.
Showing up to 300 most recent insider transactions from the last 12 months.
| Insider | Symbol | Class | Transaction | % | Value $ | * Price $ | Shares | Shares Owned | Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|---|
| Eric Weisblum | SILO | Common Stock | Purchase | 2.36% | $2,075 | $0.4150 | 5,000 | 216,932 | 15 Dec 2025 | Direct |
| Eric Weisblum | SILO | Common Stock | Purchase | 0.47% | $365 | $0.3650 | 1,000 | 211,932 | 21 Nov 2025 | Direct |
| Eric Weisblum | SILO | Common Stock | Purchase | 0.48% | $370 | $0.3700 | 1,000 | 210,932 | 20 Nov 2025 | Direct |
| Eric Weisblum | SILO | Common Stock | Purchase | 2.19% | $1,822 | $0.4050 | 4,500 | 209,932 | 19 Nov 2025 | Direct |
| Eric Weisblum | SILO | Common Stock | Purchase | 3.79% | $3,025 | $0.4033 | 7,500 | 205,432 | 18 Nov 2025 | Direct |
| Eric Weisblum | SILO | Common Stock | Purchase | 5.32% | $4,329 | $0.4329 | 10,000 | 197,932 | 27 May 2025 | Direct |
| Wayne Linsley | SILO | Options (right to buy) | Award | 1459.8% | 50,000 | 53,425 | 23 May 2025 | Direct | ||
| Kevin Munoz | SILO | Options (right to buy) | Award | 1459.8% | 50,000 | 53,425 | 23 May 2025 | Direct | ||
| Daniel E. Ryweck | SILO | Options (right to buy) | Award | 1000% | 50,000 | 55,000 | 23 May 2025 | Direct | ||
| Eric Weisblum | SILO | Options (right to buy) | Award | 106.4% | 200,000 | 387,932 | 23 May 2025 | Direct | ||
| Jeff Pavell | SILO | Options (right to buy) | Award | 50,000 | 50,000 | 23 May 2025 | Direct |
* An asterisk sign (*) next to the price indicates that the price is likely invalid.